Status:
COMPLETED
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Ovarian Cancer
Primary Peritoneal Cancer
Eligibility:
FEMALE
35+ years
Phase:
PHASE1
Brief Summary
This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based thera...
Eligibility Criteria
Inclusion
- Patient has ovarian, primary peritoneal, or fallopian tube cancer
- Patient has first or subsequent relapse
- Patient has had at least on prior platinum-based treatment for ovarian cancer
- Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum
- Patient is not pregnant
Exclusion
- Patient has had abdominal surgery within the last 6 weeks
- Patient has life expectancy \< 6 months
- Patient has had radiotherapy to the abdomen or pelvis within the last 6 months
- Patient has poorly controlled diabetes
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00959582
Start Date
September 1 2009
End Date
October 1 2011
Last Update
January 22 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.